{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:15:05Z","timestamp":1782234905238,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103975"],"award-info":[{"award-number":["82103975"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173660"],"award-info":[{"award-number":["82173660"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ21H300005"],"award-info":[{"award-number":["LQ21H300005"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LR21H300003"],"award-info":[{"award-number":["LR21H300003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["Q22H302109"],"award-info":[{"award-number":["Q22H302109"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejmech.2022.114257","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T17:33:12Z","timestamp":1648315992000},"page":"114257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells"],"prefix":"10.1016","volume":"235","author":[{"given":"Bingxue","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2191-9182","authenticated-orcid":false,"given":"Yongjin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2893-6957","authenticated-orcid":false,"given":"Weihao","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuqiu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shike","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-9214","authenticated-orcid":false,"given":"Jinxin","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yize","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexian","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2178-4372","authenticated-orcid":false,"given":"Xiaowu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5185-4696","authenticated-orcid":false,"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114257_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33762","article-title":"Epidemiology, genetics and treatment of multiple myeloma and precursor diseases","volume":"149","author":"Hemminki","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114257_bib2","first-page":"209","article-title":"Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2022.114257_bib3","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch Arztebl. Int.t"},{"key":"10.1016\/j.ejmech.2022.114257_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"33","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114257_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ejmech.2022.114257_bib6","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114257_bib7","doi-asserted-by":"crossref","first-page":"180037","DOI":"10.1098\/rsob.180037","article-title":"Cancer immunotherapy: broadening the scope of targetable tumours","volume":"8","author":"Bulk","year":"2018","journal-title":"Open Biol."},{"key":"10.1016\/j.ejmech.2022.114257_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2174\/1568009617666170214104426","article-title":"Immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2022.114257_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ejmech.2022.114257_bib10","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2022.114257_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114257_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/2040620716657993","article-title":"Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab","volume":"7","author":"Einsele","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ejmech.2022.114257_bib13","first-page":"139","article-title":"Hitting a moving target: inhibition of the nuclear export receptor XPO1\/CRM1 as a therapeutic approach in cancer","volume":"1","author":"Sendino","year":"2018","journal-title":"Cancer. Drug. Resist."},{"key":"10.1016\/j.ejmech.2022.114257_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.leukres.2014.10.003","article-title":"CRM1 as a new therapeutic target for non-Hodgkin lymphoma","volume":"39","author":"Han","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2022.114257_bib15","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/sigtrans.2016.10","article-title":"Inhibiting cancer cell hallmark features through nuclear export inhibition","volume":"1","author":"Sun","year":"2016","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2022.114257_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-015-0002-5","article-title":"Selective inhibitors of nuclear export (SINE) in hematological malignancies","volume":"4","author":"Das","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114257_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114257_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2014.04.005","article-title":"Clinical translation of nuclear export inhibitors in cancer","volume":"27","author":"Senapedis","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2022.114257_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ceb.2015.04.012","article-title":"Nuclear transport factors: global regulation of mitosis","volume":"35","author":"Forbes","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114257_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114257_bib21","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2174\/092986708786242859","article-title":"CRM1-mediated nuclear export of proteins and drug resistance in cancer","volume":"15","author":"Turner","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114257_bib22","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.2174\/1381612811319120018","article-title":"Targeting the nuclear transport machinery by rational drug design","volume":"19","author":"Mao","year":"2013","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2022.114257_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fphar.2020.00625","article-title":"Small molecule inhibitors of CRM1","volume":"11","author":"Ferreira","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114257_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/sci.2019.02.03","article-title":"The past, present, and future of CRM1\/XPO1 inhibitors","volume":"6","author":"Wang","year":"2019","journal-title":"Stem Cell Invest."},{"key":"10.1016\/j.ejmech.2022.114257_bib25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.1217203110","article-title":"Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1","volume":"110","author":"Sun","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114257_bib26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","article-title":"Phase I trial of elactocin","volume":"74","author":"Newlands","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114257_bib27","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1021\/acs.jmedchem.0c01675","article-title":"Structure-guided design of the first noncovalent small-molecule inhibitor of CRM1","volume":"64","author":"Lei","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114257_bib28","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.18632\/oncotarget.6495","article-title":"A\u00a0method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds","volume":"7","author":"Crochiere","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114257_bib29","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-16-1580","article-title":"The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia","volume":"23","author":"Vercruysse","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114257_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","article-title":"KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells","volume":"31","author":"Etchin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114257_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/14740338.2020.1713088","article-title":"Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?","volume":"19","author":"Nishihoria","year":"2020","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2022.114257_bib32","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1021\/ja9097093","article-title":"Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport","volume":"132","author":"Bonazzi","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114257_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2012.219","article-title":"Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells","volume":"27","author":"Etchin","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114257_bib34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejmech.2018.11.017","article-title":"Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: a critical review","volume":"162","author":"Zhao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114257_bib35","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1248\/cpb.c16-00614","article-title":"Novel sulfonamide derivatives carrying a biologically active 3,4-dimethoxyphenyl moiety as VEGFR-2 inhibitors, chem","volume":"64","author":"Ghorab","year":"2016","journal-title":"Pharm. Bull."},{"key":"10.1016\/j.ejmech.2022.114257_bib36","doi-asserted-by":"crossref","first-page":"104279","DOI":"10.1016\/j.bioorg.2020.104279","article-title":"Synthesis of N-phenylsulfonamide derivatives and investigation of some esterase enzymes inhibiting properties","volume":"104","author":"Kazancioglu","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114257_bib37","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1021\/acs.jmedchem.7b00731","article-title":"Discovery of novel and highly selective inhibitors of calpain for the treatment of alzheimer's disease: 2-(3-phenyl-1H-pyrazol-1-yl)-nicotinamides","volume":"60","author":"Kling","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114257_bib38","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1016\/j.tetlet.2005.05.056","article-title":"Convenient fluorination of nitro and nitrile compounds with Selectfluor","volume":"46","author":"Peng","year":"2005","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.ejmech.2022.114257_bib39","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1021\/ol1019713","article-title":"New synthesis of fluorinated pyrazoles","volume":"12","author":"Surmont","year":"2010","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2022.114257_bib40","series-title":"Nuclear Transport Modulators and Uses Thereof","author":"Baloglu","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114257_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/cas.12430","article-title":"Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma","volume":"105","author":"Yoshimura","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejmech.2022.114257_bib42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-021-02044-z","article-title":"XPO1\/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor","volume":"40","author":"Pan","year":"2021","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114257_bib43","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41331","article-title":"Distinct RanBP1 nuclear export and cargo dissociation mechanisms between fungi and animals","volume":"8","author":"Li","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2022.114257_bib44","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1128\/MCB.20.10.3510-3521.2000","article-title":"Facilitated nucleocytoplasmic shuttling of the ran binding protein RanBP1","volume":"20","author":"Plafker","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114257_bib45","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2174\/138955709788452694","article-title":"Advances in the integration of drug metabolism into the lead optimization paradigm","volume":"9","author":"Korfmacher","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114257_bib46","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/138920007782798207","article-title":"The conduct of drug metabolism studies considered good practice (II): in\u00a0vitro experiments","volume":"8","author":"Jia","year":"2007","journal-title":"Curr. Drug Metabol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422001593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422001593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:41:34Z","timestamp":1759329694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422001593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":46,"alternative-id":["S0223523422001593"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114257","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114257"}}